PURPOSE: Fifty percent of patients develop chronic gastrointestinal (GI) symptoms following pelvic radiotherapy that adversely affect quality of life. Fewer than 20 % are referred to a gastroenterologist. We aimed to determine if structured gastroenterological evaluation is of benefit to this patient group. METHODS: Sixty patients with GI symptoms at ≥ 6 months after radical pelvic radiotherapy were identified prospectively from oncology clinics in this service evaluation. Those requiring urgent investigation were excluded. Patients were assessed at baseline using patient-reported questionnaires: inflammatory bowel disease questionnaire (IBDQ), Vaizey incontinence questionnaire, and the Common Terminology Criteria for Adverse Events (CTCAE) pelvis questionnaire. Participants were referred for gastroenterological evaluation using an algorithmic approach. Further assessments were made at 3 and 6 months. RESULTS: Twenty men and 36 women with primary gynecological (31), urological (17), or lower GI (8) tumors were included (mean age, 58.5 years). Median time from radiotherapy to baseline assessment was 3.0 years. Multiple GI symptoms were reported (median, 8; range, 4-16) including frequency, urgency, loose stool, fecal incontinence, flatulence, bloating/distension, and rectal bleeding. Common diagnoses included radiation proctopathy, bile acid malabsorption, diverticulosis, and colonic polyps. Statistically significant improvements in all questionnaire scores between baseline and 6 months were found: IBDQ (p = 0.014), Vaizey (p < 0.0005), and CTCAE rectum-bowel subset (p = 0.001). CONCLUSIONS: Gastroenterological evaluation identifies significant, potentially treatable diagnoses in patients who develop chronic GI symptoms following pelvic radiotherapy. Some findings are incidental and unrelated to previous cancer treatment. Radiation-induced GI symptoms have historically been considered "untreatable." We report the first data to show that structured gastroenterological assessment has the potential to improve outcome by identifying diagnoses and facilitating focused treatment.
PURPOSE: Fifty percent of patients develop chronic gastrointestinal (GI) symptoms following pelvic radiotherapy that adversely affect quality of life. Fewer than 20 % are referred to a gastroenterologist. We aimed to determine if structured gastroenterological evaluation is of benefit to this patient group. METHODS: Sixty patients with GI symptoms at ≥ 6 months after radical pelvic radiotherapy were identified prospectively from oncology clinics in this service evaluation. Those requiring urgent investigation were excluded. Patients were assessed at baseline using patient-reported questionnaires: inflammatory bowel disease questionnaire (IBDQ), Vaizey incontinence questionnaire, and the Common Terminology Criteria for Adverse Events (CTCAE) pelvis questionnaire. Participants were referred for gastroenterological evaluation using an algorithmic approach. Further assessments were made at 3 and 6 months. RESULTS: Twenty men and 36 women with primary gynecological (31), urological (17), or lower GI (8) tumors were included (mean age, 58.5 years). Median time from radiotherapy to baseline assessment was 3.0 years. Multiple GI symptoms were reported (median, 8; range, 4-16) including frequency, urgency, loose stool, fecal incontinence, flatulence, bloating/distension, and rectal bleeding. Common diagnoses included radiation proctopathy, bile acid malabsorption, diverticulosis, and colonic polyps. Statistically significant improvements in all questionnaire scores between baseline and 6 months were found: IBDQ (p = 0.014), Vaizey (p < 0.0005), and CTCAE rectum-bowel subset (p = 0.001). CONCLUSIONS: Gastroenterological evaluation identifies significant, potentially treatable diagnoses in patients who develop chronic GI symptoms following pelvic radiotherapy. Some findings are incidental and unrelated to previous cancer treatment. Radiation-induced GI symptoms have historically been considered "untreatable." We report the first data to show that structured gastroenterological assessment has the potential to improve outcome by identifying diagnoses and facilitating focused treatment.
Authors: H Jervoise N Andreyev; Andrew Wotherspoon; James W Denham; Martin Hauer-Jensen Journal: Scand J Gastroenterol Date: 2010-12-29 Impact factor: 2.423
Authors: Tibor Hlavaty; Philippe Persoons; Severine Vermeire; Marc Ferrante; Marie Pierik; Gert Van Assche; Paul Rutgeerts Journal: Inflamm Bowel Dis Date: 2006-03 Impact factor: 5.325
Authors: H Jervoise N Andreyev; Panagiotis Vlavianos; Peter Blake; David Dearnaley; Andrew R Norman; Diana Tait Journal: Int J Radiat Oncol Biol Phys Date: 2005-08-01 Impact factor: 7.038
Authors: Mark Glover; Gary R Smerdon; H Jervoise Andreyev; Barbara E Benton; Pieter Bothma; Oliver Firth; Lone Gothard; John Harrison; Mihaela Ignatescu; Gerard Laden; Sue Martin; Lauren Maynard; Des McCann; Christine E L Penny; Spencer Phillips; Grace Sharp; John Yarnold Journal: Lancet Oncol Date: 2015-12-17 Impact factor: 41.316
Authors: Urszula M Cytlak; Douglas P Dyer; Jamie Honeychurch; Kaye J Williams; Mark A Travis; Timothy M Illidge Journal: Nat Rev Immunol Date: 2021-07-01 Impact factor: 53.106
Authors: H Jervoise N Andreyev; Amyn Lalji; Kabir Mohammed; Ann C G Muls; David Watkins; Sheela Rao; Naureen Starling; Ian Chau; Sarah Cruse; Ville Pitkaaho; Jennifer Matthews; Laura Caley; Victoria Pittordou; Carolyn Adams; Linda Wedlake Journal: Support Care Cancer Date: 2020-07-16 Impact factor: 3.603